Rathbones Group PLC Purchases 31,529 Shares of Boston Scientific Corporation $BSX

Rathbones Group PLC grew its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 1.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,281,977 shares of the medical equipment provider’s stock after buying an additional 31,529 shares during the period. Boston Scientific accounts for approximately 0.9% of Rathbones Group PLC’s holdings, making the stock its 27th biggest position. Rathbones Group PLC owned 0.15% of Boston Scientific worth $222,789,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of BSX. Dynamic Technology Lab Private Ltd bought a new position in shares of Boston Scientific in the 3rd quarter worth about $2,352,000. Vinva Investment Management Ltd boosted its stake in Boston Scientific by 83.2% during the third quarter. Vinva Investment Management Ltd now owns 124,760 shares of the medical equipment provider’s stock worth $12,107,000 after acquiring an additional 56,645 shares in the last quarter. Parallel Advisors LLC boosted its stake in Boston Scientific by 2.8% during the third quarter. Parallel Advisors LLC now owns 16,825 shares of the medical equipment provider’s stock worth $1,643,000 after acquiring an additional 455 shares in the last quarter. CreativeOne Wealth LLC grew its holdings in Boston Scientific by 30.4% in the third quarter. CreativeOne Wealth LLC now owns 16,515 shares of the medical equipment provider’s stock worth $1,612,000 after purchasing an additional 3,848 shares during the period. Finally, Rhenman & Partners Asset Management AB increased its stake in shares of Boston Scientific by 48.0% during the third quarter. Rhenman & Partners Asset Management AB now owns 438,000 shares of the medical equipment provider’s stock valued at $42,762,000 after purchasing an additional 142,000 shares in the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Board increased share buyback authorization to $5 billion, which supports EPS and provides a buyback backstop that can limit downside and return capital to shareholders. Boston Scientific (BSX) Raises Share Buyback Authorization To $5B
• Positive Sentiment: Boston Scientific will host an investor event and live webcast at the American College of Cardiology meeting on March 28 to discuss clinical data — a chance for management to highlight growth drivers and reassure investors on clinical/market progress. Boston Scientific to host investor event at the 75th Annual Scientific Session of the American College of Cardiology
• Neutral Sentiment: Coverage and commentaries note BSX is about 6% lower since last earnings — analysts point to mixed cues from the earnings release (modest beat on EPS, revenue roughly in line, and guidance ranges) and market reactions to forward views; this helps explain recent selling pressure but is not new company-specific bad news. Why Is Boston Scientific (BSX) Down 6% Since Last Earnings Report?
• Negative Sentiment: A wave of securities-class-action filings and investor-alert notices from multiple law firms allege wrongdoing for purchasers between July 23, 2025 and Feb 3, 2026 — several firms (Robbins LLP, Rosen, Bernstein Liebhard, Faruqi & Faruqi, Levi & Korsinsky, Gainey McKenna & Egleston) have issued notices and reminder deadlines, creating a legal overhang that can pressure the stock and increase uncertainty/costs. BSX Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Lawsuit Rosen Law Firm Urges Boston Scientific Stockholders to Contact the Firm Bernstein Liebhard Investor Alert

Wall Street Analyst Weigh In

BSX has been the topic of several recent research reports. Mizuho cut their price target on Boston Scientific from $140.00 to $115.00 and set an “outperform” rating on the stock in a research note on Thursday, February 5th. Barclays dropped their target price on Boston Scientific from $136.00 to $124.00 and set an “overweight” rating on the stock in a report on Tuesday, February 3rd. Evercore reduced their price target on Boston Scientific from $112.00 to $96.00 and set an “outperform” rating for the company in a report on Thursday, February 5th. Robert W. Baird lowered their price target on Boston Scientific from $118.00 to $101.00 and set an “outperform” rating for the company in a research report on Thursday, February 5th. Finally, UBS Group dropped their price target on shares of Boston Scientific from $140.00 to $120.00 and set a “buy” rating on the stock in a research note on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $108.36.

Boston Scientific Trading Down 2.4%

Shares of NYSE:BSX opened at $71.24 on Friday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. Boston Scientific Corporation has a 1 year low of $70.75 and a 1 year high of $109.50. The company has a market cap of $105.71 billion, a P/E ratio of 36.72, a PEG ratio of 1.00 and a beta of 0.69. The stock’s fifty day moving average price is $85.03 and its 200-day moving average price is $94.55.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. The business had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.Boston Scientific’s revenue was up 15.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Sell-side analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.